{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:20:45Z","timestamp":1769923245626,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias","award":["CP08\/00172"],"award-info":[{"award-number":["CP08\/00172"]}]},{"name":"Redes Tem\u00e1ticas de Investigaci\u00f3n en SIDA","award":["ISCIII RETIC RD12\/0017\/0029"],"award-info":[{"award-number":["ISCIII RETIC RD12\/0017\/0029"]}]},{"name":"Consejer\u00eda Andaluza de Salud","award":["PI-0278-2010"],"award-info":[{"award-number":["PI-0278-2010"]}]},{"name":"Pfizer\/ViiV Healthcare","award":["WS2425049"],"award-info":[{"award-number":["WS2425049"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.antiviral.2014.08.011","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T20:42:46Z","timestamp":1409172166000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Maintenance of virologic efficacy and decrease in levels of \u03b22-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy"],"prefix":"10.1016","volume":"111","author":[{"given":"M. Concepci\u00f3n","family":"Romero-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana I.","family":"\u00c1lvarez-R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Bernal-Morell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Genebat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Rafii-El-Idrissi","family":"Benhnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Bravo-Urbieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Galera-Pe\u00f1aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca S.","family":"de Pablo-Bernal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Antonia","family":"Abad-Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Leal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezequiel","family":"Ruiz-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.08.011_b0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/fvl.10.89","article-title":"Atazanavir\/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults","volume":"6","author":"Achenbach","year":"2011","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2014.08.011_b0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/QAI.0b013e3181c5c83b","article-title":"CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2","volume":"54","author":"Asmuth","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2014.08.011_b0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2013.10.021","article-title":"Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy","volume":"232","author":"Barbour","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.antiviral.2014.08.011_b0025","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.1991.03460040048027","article-title":"Genital human papillomavirus infection in female university students as determined by a PCR-based method","volume":"265","author":"Bauer","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.08.011_b0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/eri.09.66","article-title":"The CASTLE study: atazanavir\/r versus lopinavir\/r in antiretroviral-naive patients","volume":"7","author":"Chetchotisakd","year":"2009","journal-title":"Exp. Rev. Anti Infect. Ther."},{"key":"10.1016\/j.antiviral.2014.08.011_b0035","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cca.2011.01.037","article-title":"Beta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapy","volume":"412","author":"Chitra","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.antiviral.2014.08.011_b0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4049\/jimmunol.1001911","article-title":"Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals","volume":"186","author":"Davidson","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.antiviral.2014.08.011_b0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1742-2094-10-144","article-title":"Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?","volume":"10","author":"Davidson","year":"2013","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.antiviral.2014.08.011_b0050","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s15010-008-7312-z","article-title":"Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels","volume":"36","author":"De Felipe","year":"2008","journal-title":"Infection"},{"key":"10.1016\/j.antiviral.2014.08.011_b0055","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/QAD.0b013e32833a2b02","article-title":"Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation","volume":"24","author":"De Pablo","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.08.011_b0060","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cell.2010.11.001","article-title":"Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue","volume":"143","author":"Doitsh","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2014.08.011_b0065","doi-asserted-by":"crossref","first-page":"e33925","DOI":"10.1371\/journal.pone.0033925","article-title":"Chronic immune activation in HIV-1 infection contributes to reduced interferon alpha production via enhanced CD40:CD40 ligand interaction","volume":"7","author":"Donhauser","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.08.011_b0070","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/COH.0000000000000019","article-title":"Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients","volume":"9","author":"Funderburg","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2014.08.011_b0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4690-6-27","article-title":"The Spanish HIV BioBank: a model of cooperative HIV research","volume":"6","author":"Garcia-Merino","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2014.08.011_b0080","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1128\/AAC.00507-12","article-title":"HIV-1 tropism evolution after short-term maraviroc monotherapy in HIV-1-infected patients","volume":"56","author":"Gonzalez-Serna","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.011_b0085","doi-asserted-by":"crossref","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","article-title":"Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected","volume":"6","author":"Gutierrez","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.08.011_b0090","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","author":"Hogg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.08.011_b0095","unstructured":"Hunt P, S.N., Hayes T, et al. Alexandria VA: Foundation for Retrovirology and Human Health, 2011. Immunomodulatory effects of MVC intensification in HIV-infected individuals with incomplete CD4+ T cell recovery during suppressive ART [abstract 153LB]. In: 18th Conference on Retroviruses and Opportunistic Infection, Personal communication, Boston, MA."},{"key":"10.1016\/j.antiviral.2014.08.011_b0100","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","article-title":"The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2014.08.011_b0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1310\/hct1303-119","article-title":"A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results","volume":"13","author":"Kozal","year":"2012","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.antiviral.2014.08.011_b0115","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection","volume":"5","author":"Kuller","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2014.08.011_b0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/infdis\/jit006","article-title":"Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging","volume":"207","author":"Leeansyah","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.011_b0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/COH.0b013e32835c7134","article-title":"Soluble biomarkers of HIV transmission, disease progression and comorbidities","volume":"8","author":"Leeansyah","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.antiviral.2014.08.011_b0130","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/QAD.0b013e328354f4fb","article-title":"Inflammation markers after randomization to abacavir\/lamivudine or tenofovir\/emtricitabine with efavirenz or atazanavir\/ritonavir","volume":"26","author":"McComsey","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.08.011_b0135","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/infdis\/jit025","article-title":"Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14","volume":"207","author":"Mendez-Lagares","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.011_b0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/QAI.0b013e31827b51b5","article-title":"Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study","volume":"62","author":"Mills","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2014.08.011_b0145","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study","volume":"370","author":"Mocroft","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.08.011_b0150","doi-asserted-by":"crossref","first-page":"e77379","DOI":"10.1371\/journal.pone.0077379","article-title":"Decreased chronic morbidity but elevated HIV associated cytokine levels in HIV-infected older adults receiving HIV treatment: benefit of enhanced access to care?","volume":"8","author":"Mutevedzi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.08.011_b0155","doi-asserted-by":"crossref","first-page":"e44411","DOI":"10.1371\/journal.pone.0044411","article-title":"Are plasma biomarkers of immune activation predictive of HIV progression: a longitudinal comparison and analyses in HIV-1 and HIV-2 infections?","volume":"7","author":"Nyamweya","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2014.08.011_b0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1468-1293.2012.01000.x","article-title":"Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study","volume":"13","author":"Olmo","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.antiviral.2014.08.011_b0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/QAD.0b013e32835cae9c","article-title":"Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population","volume":"27","author":"Rodger","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2014.08.011_b0170","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1128\/AAC.01406-12","article-title":"Effect of maraviroc on HIV disease progression-related biomarkers","volume":"56","author":"Romero-Sanchez","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.08.011_b0175","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2014.08.011_b0180","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e3182a03d95","article-title":"Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir\/ritonavir in a pilot study","volume":"64","author":"Taiwo","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2014.08.011_b0185","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/vim.2006.19.759","article-title":"Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure","volume":"19","author":"Vallejo","year":"2006","journal-title":"Viral Immunol."},{"key":"10.1016\/j.antiviral.2014.08.011_b0195","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2119\/molmed.2012.00206","article-title":"CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection","volume":"18","author":"Westrop","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.antiviral.2014.08.011_b0200","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-med-052010-145454","article-title":"CCR5 antagonism in HIV infection: current concepts and future opportunities","volume":"63","author":"Wilkin","year":"2012","journal-title":"Annu. Rev. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002484?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002484?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:18:47Z","timestamp":1717287527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214002484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":37,"alternative-id":["S0166354214002484"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.08.011","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance of virologic efficacy and decrease in levels of \u03b22-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}